Report 1 of 1 · 3/17/2026
· 3/17/2026
This report finished before verdicts existed. Its conclusions are in the full report.
Research question and scope
This report addresses the evidence that vanillin (4-hydroxy-3-methoxybenzaldehyde) exerts anticancer activity, with emphasis on: (1) systematic collation of preclinical in vitro and in vivo studies reporting growth inhibition, apoptosis, cell-cycle effects, migration/invasion suppression and effective concentrations; (2) synthesis of molecular mechanisms and reported cellular targets (NF-κB, MAPK/ASK1-p38, PI3K/Akt, caspases, ROS/mitochondria, NNMT and related pathways); (3) chemoinformatic evidence and plausible target hypotheses based on publicly available bioactivity databases; (4) ADME/metabolism considerations relevant for translation; and (5) a prioritized set of experimental validations and translational recommendations. The review includes studies reporting direct experimental data (cellular assays, biochemical readouts, and animal models) and database-derived activity records.
Summary of key findings (high-level)
Preclinical evidence indicates reproducible anticancer phenotypes for vanillin across multiple cancer contexts: inhibition of proliferation, induction of apoptosis, suppression of migration/invasion, and enhancement of chemotherapy sensitivity (notably with 5-fluorouracil and TRAIL). These effects have been documented in colorectal cancer (HT-29, SW480), melanoma (B16F10), cervical cancer (HeLa), hepatocellular carcinoma (HepG2), and other cell models
Reported potencies vary widely across studies. Some reports show effects in the low- to mid-micromolar range (e.g., HT-29 and B16F10 reports with effective concentrations 5–33 μM), while several rigorous studies report effective concentrations and IC50 values in the low-millimolar range (≈2.5–4 mM) in colorectal models (SW480, HT-29)
Mechanistically, vanillin has been reported to inhibit NF-κB signaling (reduced p65 phosphorylation and transcriptional activity), to modulate MAPK signaling (activation of ASK1-p38 in some CRC contexts), to inhibit PI3K enzymatic activity and downstream Akt phosphorylation (in migration/angiogenesis contexts), to increase ROS and induce mitochondrial apoptosis (Bax up, Bcl-2 down, cytochrome c release, caspase-9/3 activation), and to downregulate nicotinamide N-methyltransferase (NNMT), which links metabolism to chemoresistance
Public bioactivity resources identify several biochemical activities or reported interactions for vanillin at relatively high concentrations (e.g., bitter taste receptors TAS2R14/20/39, TRPV3 activation) and curated inhibitory entries in ChEMBL for targets detected in biochemical screens (e.g., modest inhibition of GABA transaminase; patent-derived AlphaScreen data for TRIM24/TRIM33 bromodomain hits). These entries suggest vanillin is polypharmacological at high concentrations, and that plausible protein-level interactions exist for follow-up binding assays
In vivo antitumor activity has been reported in multiple models (murine B16F10 melanoma, BALB/c/nu xenografts of SW480/HT-29) with intraperitoneal dosing (commonly 50–100 mg/kg/day or 100 mg/kg every other day), tumor-growth inhibition, and reduced NF-κB staining or increased TUNEL apoptosis in tumors. Toxicology data are limited but historically suggest relatively low acute toxicity at moderate doses (cited reports up to 300 mg/kg without overt lethality)
The body of evidence therefore supports vanillin as a multi-target small molecule with demonstrable anticancer phenotypes in preclinical models, but with variable potencies and limited translational readiness due to pharmacokinetic/metabolic constraints and heterogeneity in experimental conditions.
Summary table of primary preclinical results (selected, annotated)
| Study (selected) | Model / cell line | Reported effective concentration or IC50 | Assay(s) & observed phenotypes | Key mechanistic readouts | Citation |
|---|---|---|---|---|---|
| Pharmacognosy Magazine (Phcog) — HT-29 CRC | HT-29 (human colorectal adenocarcinoma) | IC50 = 20 μM (MTT, 5–20 μM tested) | MTT viability loss, AO/EtBr and Hoechst nuclear fragmentation, ↓Δψm (Rhodamine‑123) | ↑Bax, ↑cytochrome c, ↑caspase‑9/3, ↓Bcl‑2 (WB) | |
| Spandidos Oncology Reports (2021) — CRC NNMT study | HT‑29 / SW480 (and NNMT-over/knockdown variants) | IC50: HT‑29/NC 2.54 mM; SW480/NC 4.02 mM; SW480/NNMT 3.15 mM (CCK‑8, 48 h) | Reduced viability/colony formation; apoptosis (Annexin V), synergy with 5‑Fu (lowered 5‑Fu IC50) | ↓NNMT mRNA/protein/activity (↓1‑MNA by LC‑MS), ↑p‑ASK1, ↑p‑p38, ↑ROS (DCFH‑DA), ↓Δψm (JC‑1), caspase activation; SB203580 and NAC rescue tests | |
| In Vivo Research (Advanced Biomedical Research / B16F10) | B16F10 (mouse melanoma) in vitro and s.c. tumor in C57BL/6 mice | In vitro: 1–5 μg/mL (~6.6–33 μM) decreased viability; In vivo: IP 50 or 100 mg/kg/day ×10 d reduced tumor volume/weight | MTT in vitro; tumor volume reduction (control 827.4 ± 91.2 mm³ → 50 mg/kg 234.8 ± 29.6 mm³), TUNEL ↑ | Tumor IHC: NF‑κB reduced at 100 mg/kg | |
| In Vivo/In Vitro (IIAR) — TRAIL sensitization | HeLa (cervical) and TRAIL apoptosis assays in vitro | Vanillin non-toxic 1–2 mM; sensitized TRAIL apoptosis at 2 mM pretreatment | WST‑1 viability, luciferase NF‑κB reporter, caspase‑3 and PARP cleavage (WB); apoptosis increase when combined with TRAIL | ↓NF‑κB transcriptional activity (luciferase), ↓p65 Ser536, ↑caspase‑3/PARP cleavage; no effect on Akt p‑Ser473 in that system | |
| Journal of Agric. Food Chem. (abstract) — PI3K inhibition / anti‑metastasis | Human lung cancer (migration assays), CAM angiogenesis assay | Effective concentrations not reported in abstract; biochemical PI3K inhibition observed (in vitro lipid kinase assay) | Transwell migration (HGF induced), CAM angiogenesis (in vivo) | Direct inhibition of PI3K enzymatic activity; ↓p‑Akt (in HGF signaling) | |
| HepG2 / SH‑SY5Y (Molecular Cellular Biochemistry, 2017) | HepG2 (liver) and SH‑SY5Y (neuroblastoma) | Dose‑dependent antiproliferative effect reported (no IC50 in summary) | Proliferation assays; mitochondrial and ROS assays | Computational docking suggests binding to CAMKIV active site; reported mitochondrial depolarization and apoptosis |
Notes on heterogeneity and assay dependence
The reported effective concentrations vary by orders of magnitude between studies (μM vs mM). For example, two reports on HT‑29 cells report an IC50 of ~20 μM in one study
Many studies rely on colorimetric viability assays (MTT, CCK‑8, WST‑1) and flow cytometry for apoptosis/ΔΨm/ROS; mechanistic inference is typically supported by Western blot analyses for phosphorylation status and apoptosis markers.
Visual summary: reported potencies and concentration ranges
Reported numerical IC50s and broad concentration ranges extracted from the literature are plotted below to emphasize the heterogeneity in potency claims.
Figure caption: Reported IC50 values (μM) from selected studies. Data points illustrate that some studies report low‑micromolar potencies while others report low‑millimolar potencies (note log scale to accommodate order‑of‑magnitude differences)
Figure caption: Horizontal bars show the minimum and maximum concentrations reported to produce biological effects in representative studies (μM), illustrating that effective ranges span ~5–7,000 μM across the literature
This section synthesizes experimental mechanistic data from the literature, grouped by pathway/target with representative experimental evidence and where available the assays used to support each link.
Evidence: Multiple studies report that vanillin inhibits NF‑κB activation, reduces p65 phosphorylation (Ser536), suppresses p65 nuclear translocation and NF‑κB transcriptional activity (luciferase reporter), and decreases NF‑κB staining in tumors after systemic dosing
Assays supporting this: NF‑κB luciferase reporter in HeLa cells; immunoblots for p‑p65; immunohistochemistry for NF‑κB in tumor tissue; outcome correlation with caspase activation in TRAIL‑sensitization models indicates functional consequences for apoptosis when NF‑κB is suppressed
Proposed role in anticancer activity: NF‑κB is a canonical survival and inflammation pathway; vanillin’s inhibition of NF‑κB likely sensitizes tumor cells to apoptotic stimuli (e.g., TRAIL) and reduces inflammatory/angiogenic signaling in the tumor microenvironment.
Evidence: In colorectal cancer models (SW480/HT‑29), vanillin was observed to activate ASK1 (Thr845) and p38 MAPK (Thr180/Tyr182) and to increase downstream apoptosis; p38 inhibition using SB203580 attenuated vanillin‑induced apoptosis, suggesting a causal role for ASK1‑p38 activation in these contexts
Assays supporting this: Western blot for phosphorylated ASK1/p38; chemical inhibitor (SB203580) rescue experiments; flow cytometry for apoptosis; mitochondrial potential and ROS readouts.
Interpretation: In this CRC context, ASK1‑p38 acts as a pro‑apoptotic effector downstream of oxidative stress; vanillin appears to produce oxidative stress/mitochondrial perturbation that engages ASK1‑p38 to trigger caspase activation.
Evidence: A reported study shows that vanillin inhibits PI3K enzymatic activity in vitro and reduces Akt phosphorylation in HGF‑stimulated migration models; this correlates with reduced HGF‑induced cell migration and reduced angiogenesis in a CAM assay, supporting an anti‑metastatic mechanism via direct PI3K inhibition
Assays supporting this: in vitro lipid kinase assays for PI3K activity; immunoblots for p‑Akt in HGF signaling; transwell migration assays; CAM angiogenesis assay.
Interpretation: PI3K inhibition by vanillin (biochemically measurable in some assays) provides a mechanistic route to impair migration/angiogenesis distinct from apoptosis‑inducing mechanisms.
Evidence: Several studies report dose‑dependent increases in intracellular ROS (DCFH‑DA probe), loss of mitochondrial membrane potential (JC‑1, Rhodamine‑123), release of cytochrome c, altered Bax/Bcl‑2 ratios, and activation of caspase‑9 and caspase‑3—consistent with canonical mitochondrial (intrinsic) apoptosis
Assays supporting this: Flow cytometry (DCFH‑DA for ROS; JC‑1 for ΔΨm), Western blot for cytochrome c, caspases, and Bcl‑2 family members, NAC rescue.
Interpretation: Vanillin can act as a pro‑oxidant in tumor cells (at the concentrations used in some studies), engaging intrinsic apoptosis cascades; this may be context‑dependent and influenced by cellular antioxidant capacity.
Evidence: In colorectal cancer models, vanillin downregulated nicotinamide N‑methyltransferase (NNMT) expression and enzymatic activity (measured by LC‑MS for 1‑MNA), reversing NNMT‑associated 5‑fluorouracil resistance and enhancing apoptotic responses. In vivo, vanillin (100 mg/kg IP) enhanced 5‑Fu efficacy in xenografts
Assays supporting this: RT‑qPCR and Western blot for NNMT, LC‑MS quantification of 1‑MNA, cell viability and apoptosis assays, xenograft tumor volume and TUNEL staining.
Interpretation: NNMT is a metabolic enzyme linked to chemoresistance and altered NAD metabolism; vanillin’s suppression of NNMT elucidates a metabolism‑targeted adjuvant mechanism that can be tested as a biomarker‑led approach in CRC models.
Representative mechanistic diagram (textual schematic)
Extracellular/RTK signals (HGF) → PI3K → Akt → pro‑migration/angiogenesis (vanillin: direct PI3K inhibition → ↓p‑Akt → ↓migration/angiogenesis)
Cellular stress/ROS → ASK1 → p38 MAPK → mitochondrial permeabilization → cytochrome c release → caspase‑9 → caspase‑3 → apoptosis (vanillin: ↑ROS/ΔΨm loss → ASK1‑p38 activation → apoptosis; NAC/SB203580 rescue experiments support this order in CRC cells)
Pro‑survival NF‑κB (p65) activity → transcriptional survival/anti‑apoptotic gene expression (Bcl‑2, XIAP, inflammatory cytokines) (vanillin: ↓p‑p65, ↓NF‑κB reporter activity → sensitization to TRAIL/apoptosis)
Metabolic node: NNMT activity → 1‑MNA → chemoresistance/altered NAD biochemistry (vanillin: ↓NNMT expression/activity → lower 1‑MNA → restored 5‑Fu sensitivity)
(These pathways are not mutually exclusive; in many experimental contexts vanillin appears to act pleiotropically by combining metabolic, redox, and signaling perturbations.)
Public bioactivity annotations and patent screens provide guidance on plausible protein interactions that could explain some observed phenotypes or serve as starting points for target‑based validation.
Key database observations
PubChem identifies vanillin (CID 1183) as a small aromatic aldehyde with recorded activations of certain chemosensory receptors at high concentrations and links to biochemical assay data; ChEMBL lists compound CHEMBL13883 with several curated bioactivity entries from the literature and patent records including modest inhibition of GABA transaminase and reported AlphaScreen hits against bromodomain PHD pockets (TRIM24/TRIM33)
IUPHAR/GtoPdb records report vanillin agonist activity at bitter taste receptors TAS2R14/20/39 and TRPV3 activation at very high concentrations (EC50/pEC50 values in the 10⁻⁴–10⁻³ M range), implying that receptor engagement often requires concentrations that overlap with the high‑millimolar cellular concentrations reported in some anticancer studies
Implications for plausible direct protein targets in cancer biology
PI3K: a biochemical lipid kinase assay reported direct PI3K inhibition by vanillin, providing a clear, testable direct target that links to observed anti‑migration and anti‑angiogenesis phenotypes
Bromodomain/PHD targets (TRIM24/TRIM33): patent AlphaScreen reports indicate that vanillin can score in bromodomain PHD assays; if reproducible, this could link to transcriptional reprogramming with downstream impacts on proliferation and survival in tumors
NNMT: while not a direct binding target reported in biochemical screens for vanillin, vanillin downregulates NNMT expression and activity in CRC cells (measured by LC‑MS for 1‑MNA). This suggests either a transcriptional/regulatory mechanism or an indirect effect via metabolic/oxidative stress, rather than a high‑affinity direct enzymatic inhibition
Structure–activity relationships (SAR) for vanillin and simple analogs (qualitative)
Functional groups: The aldehyde (formyl) group and the 4‑hydroxy/3‑methoxy substitution pattern on the benzaldehyde core appear important for certain activities (e.g., PI3K inhibition noted to depend on the aldehyde/ketone presence in structure in the anti‑metastasis study)
Lipophilicity and polarity: Vanillin is a small, moderately polar aromatic aldehyde (MW ~152.15 Da) that is readily conjugated (glucuronidation/sulfation) in vivo, which limits systemic exposure. Substitution to increase lipophilicity or to protect the phenolic/aldehyde groups (e.g., etherification, ester prodrugs) could improve cell permeability and alter metabolic stability but will change target engagement profiles—thus SAR optimization must be guided by parallel potency and ADME testing.
Recommended in silico and in vitro follow‑up to prioritize direct targets
Conduct targeted biochemical screens using purified proteins: PI3K lipid kinase assays (multiple isoforms), bromodomain/PHD AlphaScreen or TRIM family binding assays, CAMKIV kinase assays, and selected dehydrogenase/aminotransferase enzymatic assays indicated by ChEMBL.
If access to docking is available, structure‑based docking against PI3K catalytic sites and bromodomain/PHD structures (TRIM24/TRIM33) would prioritize which targets are most likely to bind vanillin in a drug‑like pose and to inform ligand optimization (e.g., growing from the aldehyde/phenolic core)
Pharmacokinetics and metabolism
Oral bioavailability in rodents is poor. A rat pharmacokinetic study reported oral bioavailability ~7.6% after 100 mg/kg PO with Tmax ~4 h and half‑life ~10.3 h (plasma Cmax ≈ 290 ng/mL), indicating low systemic exposure after oral dosing and significant first‑pass metabolism
Major metabolites: vanillic acid, vanillyl alcohol, vanilloylglycine, and a variety of conjugated metabolites (glucuronide/sulfate). These transformations are enzymatic (UDP‑glucuronosyltransferases and sulfotransferases) and likely rapid in humans as in rodents; the metabolic liability explains the limited plasma exposures achievable via oral dosing.
Implications for pharmacology and dosing
In vitro effective concentrations reported in some studies (low μM) are plausibly reachable in plasma for short durations only with optimized parenteral dosing or with formulations that minimize first‑pass metabolism; however, many reported anticancer effects require concentrations in the low‑millimolar range which exceed practical systemic exposure without regional or local delivery strategies.
Conversion to glucuronide/sulfate metabolites raises the possibility that parent compound exposure is transient and that active metabolites may contribute to or oppose observed cellular effects. Therefore, direct measurement of parent vs metabolite concentrations in plasma and tumor tissue is essential in preclinical PK/PD studies.
Formulation and routes of administration
Parenteral delivery (IP, IV) has been used in animal efficacy studies with antitumor effects (e.g., IP 50–100 mg/kg) and may evade first‑pass metabolism, producing higher systemic concentrations in rodents; but human translation would require rigorous toxicology and safety evaluation for such exposures
Alternative strategies to improve exposure and tumor delivery include prodrug approaches (e.g., esterification to protect phenolic/aldehyde groups), nanoparticle or liposomal formulations, or local/regional delivery (intratumoral or intra‑arterial) for accessible tumors.
This section proposes a prioritized experimental plan to validate mechanisms, establish robust potency estimates, and generate translationally relevant PK/PD data.
A. Standardized in vitro potency and phenotype confirmation (tier 1)
Objective: Generate reproducible IC50/EC50 estimates across representative cancer cell lines using standardized conditions.
Methods:
B. Mechanistic cellular assays (tier 2)
C. Biochemical binding and target engagement (tier 3)
Objective: Test direct binding or inhibition of prioritized proteins (PI3K isoforms, CAMKIV, TRIM24/TRIM33 bromodomains, selected kinases) to separate direct from indirect mechanisms.
Methods:
D. In vivo efficacy, PK/PD and toxicity (tier 4)
Objective: Establish exposure–response in relevant xenograft models and define tolerability.
Methods:
E. Target validation via genetics (tier 5)
Vanillin an active constituent from Vanilla bean induces apoptosis and inhibits proliferation in human colorectal adenocarcinoma cell line. Pharmacognosy Magazine (Phcog). Detailed in vitro HT‑29 study reporting MTT IC50 = 20 μM, mitochondrial depolarization, Bax/Bcl‑2 modulation and caspase activation. Useful for low‑μM potency claims and mitochondrial apoptosis evidence
Li et al., Vanillin downregulates NNMT and attenuates NNMT‑related CRC proliferation and 5‑Fu resistance (Oncology Reports / Spandidos 2021). Comprehensive mechanistic work in CRC models with detailed concentration–response, NNMT activity (1‑MNA by LC‑MS), ASK1‑p38 signaling, ROS/ΔΨm assays, and in vivo xenograft synergy with 5‑Fu (100 mg/kg vanillin i.p.). Strong evidence for an NNMT‑linked mechanism of chemosensitization
Vanillin Enhances TRAIL‑Induced Apoptosis in Cancer Cells through Inhibition of NF‑κB Activation (In Vivo / IIAR). Reports sensitization of HeLa cells to TRAIL via NF‑κB inhibition (luciferase reporter, p‑p65) and increased caspase activation at 2 mM vanillin pretreatment
The Inhibitory Effects of Vanillin on the Growth of Melanoma by Reducing Nuclear Factor‑κB Activation (Advanced Biomedical Research, 2022 / PMC9621346). Provides in vitro and in vivo tumor data (B16F10) with tumor volume reductions at IP dosing 50–100 mg/kg and reduced NF‑κB tumor IHC staining
Vanillin Suppresses Metastatic Potential of Human Cancer Cells through PI3K Inhibition and Decreases Angiogenesis in Vivo (J. Agric. Food Chem., abstract/PMID 19368348). Reports PI3K enzymatic inhibition linked to decreased Akt phosphorylation and reduced migration/angiogenesis in CAM assay; supports mechanism for anti‑metastasis activity
Vanillin binding to CAMKIV (Molecular and Cellular Biochemistry, 2017). Computational docking suggests CAMKIV interaction with observed antiproliferative and mitochondrial effects in HepG2 and SH‑SY5Y cells; provides a candidate kinase to test experimentally
ChEMBL / PubChem / GtoPdb entries for vanillin (CHEMBL13883; CID 1183) provide curated biochemical activity records, including moderate inhibitory outcomes in biochemical screens and activity at taste receptors/TRPV3 at high concentrations; these entries are a resource for planning biochemical target screens
Pharmacokinetic/metabolism resources (rat PK study and classical metabolism literature) demonstrate low oral bioavailability and rapid glucuronidation/sulfation of vanillin, which informs formulation and dosing strategies for translational studies
Major translational challenges
Discrepant potencies and question of achievable exposures: The literature reports effective concentrations from low‑micromolar to low‑millimolar ranges. Many mechanistic readouts (e.g., NF‑κB inhibition in HeLa, PI3K in biochemical assays) require high micromolar to millimolar concentrations in cellular assays. Given poor oral bioavailability and extensive first‑pass glucuronidation/sulfation, achieving systemic exposures that match the majority of reported cellular IC50s in humans would be challenging without formulation or delivery innovations
Mechanistic pleiotropy and specificity: Vanillin shows multiple activities (NF‑κB inhibition, ASK1‑p38 activation via ROS, PI3K inhibition, NNMT expression suppression, and a variety of low‑affinity biochemical hits). Distinguishing primary, drug‑like targets from off‑target or secondary stress responses is necessary for rational optimization and for minimizing toxicity.
Limited toxicity and PK data: Animal toxicity studies reported in the anticancer literature are limited in scope (short course studies, often no comprehensive GLP toxicology). Historical reports indicate low overt acute toxicity up to moderate doses in rodents, but thorough subchronic and organ‑specific toxicology, genotoxicity, and safety pharmacology are lacking for anticancer dosing regimens
Absence of clinical trials: No clinical trials of vanillin as an anticancer agent were identified in the literature search; translation to first‑in‑human studies would require a robust preclinical dossier addressing potency, selectivity, PK/PD, and safety
Gap analysis (priority gaps to address)
Safety considerations
Acute and subacute toxicity studies in rodents at efficacious doses (e.g., 50–100 mg/kg IP) should be prioritized (clinical chemistry panels, histopathology, body weight, behavior). Existing reports suggest tolerability in short studies but are not sufficient for clinical translation
Genotoxicity assays (Ames test, micronucleus) and reproductive toxicity panels should be performed before first‑in‑human dosing.
Short‑term (0–12 months)
Standardized in vitro potency campaign across key cell lines to define realistic concentration ranges (CellTiter‑Glo, colony formation) and confirm phenotype reproducibility. (Tier 1)
Biochemical target validation: PI3K lipid kinase assays (α/β/γ/δ), CAMKIV kinase assay, TRIM bromodomain AlphaScreen/DSF. Establish IC50s and binding parameters to distinguish direct vs indirect mechanisms. (Tier 3)
Mechanistic cell biology: NF‑κB reporter assays, ROS/ΔΨm assays with NAC/SB203580 rescue, and NNMT quantification (RT‑qPCR/LC‑MS). Integrate genetic validation (siRNA/CRISPR for NNMT, ASK1, p38α, PI3K subunits) to establish causality. (Tier 2 / Tier 5)
Medium‑term (6–18 months)
PK/PD study in rodents: route comparison (oral vs IP vs IV), LC‑MS quantification of parent and metabolites in plasma and tumor, and linking to PD markers (tumor NF‑κB, 1‑MNA, p‑p38). Optimize formulation (PEG vehicles, prodrugs, nanoencapsulation) if exposure is insufficient. (Tier 4)
In vivo efficacy studies with combination regimens (e.g., vanillin + 5‑Fu in CRC xenograft) using exposure‑matched dosing; include tumor PD readouts and toxicity endpoints. (Tier 4)
Long‑term (12–36 months)
Medicinal chemistry SAR: guided by biochemical target data, create analogs that retain target potency but improve metabolic stability (mask rapid glucuronidation sites) and test in parallel for ADME. Iterate with in vitro and in vivo potency/PK. Consider co‑crystal or docking data to guide structure growth for increased affinity and selectivity.
Safety package for first‑in‑human: GLP toxicology (rodent and non‑rodent), safety pharmacology, genotoxicity, and reproductive toxicity studies.
Regulatory and translational caution
Heterogeneous experimental protocols across studies (assay type, exposure duration, vehicle/solvent differences) impede direct comparison of potency values.
Many mechanistic findings are associative (e.g., NF‑κB reduction concurrent with apoptosis) and require genetic or biochemical target validation to establish primary targets.
Limited pharmacokinetic and toxicology data appropriate for translation; prior PK studies are primarily in rodents and historical metabolism literature is dated.
No clinical data were identified testing vanillin as an anticancer agent.
These limitations define the experimental priorities outlined above.
Vanillin produces reproducible anticancer phenotypes in preclinical models (growth inhibition, apoptosis, migration suppression, and chemotherapy sensitization) but reported effective concentrations vary from low‑micromolar to low‑millimolar across studies
Mechanistic evidence implicates NF‑κB inhibition, ASK1‑p38 activation downstream of ROS/mitochondrial damage, PI3K inhibition (anti‑metastatic effect), and NNMT downregulation (chemoresistance reversal) as key pathways affected by vanillin
Public bioactivity databases provide candidate direct targets (PI3K enzymatic inhibition in an in vitro lipid kinase assay; patent/AlphaScreen hits for bromodomain PHD proteins) that warrant rigorous biochemical validation
Translation is challenged by low oral bioavailability (extensive glucuronidation/sulfation), variable potency claims, and insufficient toxicity/PK data; recommended next steps include rigorous potency standardization, biochemical target validation, PK/PD linking, and medicinal chemistry to improve metabolic stability and potency
A. Quick experimental checklist (methods and reagents)
B. Representative citations
(Select primary source URLs used in the report):
End of report.
